

PROTECTING AGAINST INFLUENZA IN ADULTS

65+

INFLUENZA IS A PREVALENT, CONTAGIOUS, AND VACCINE-PREVENTABLE INFECTIOUS DISEASE IN CANADA

CONSEQUENCES OF INFLUENZA INFECTION CAN BE DEVASTATING FOR ADULTS 65+.


This age group generally has lower immune responses to infections AND typically doesn't respond to vaccines as well as younger adults.¹⁻³ This puts them at potentially higher risk of influenza-related complications, hospitalization, and death.⁴⁻⁶

SENIORS REPRESENT

 **15%** of Canada's population⁷

YET, IN 2014-2015, ADULTS 65+ ACCOUNTED FOR:

 **70%** of influenza-related hospitalizations⁸

 **91%** of influenza-related deaths⁸



74% OF CANADIANS 65+ reported having at least 1 chronic condition*, many of which may put them at high risk for influenza and its complications.^{4,9}

*Arthritis, asthma, cancer, chronic pain, depression, diabetes, emphysema/COPD, heart disease, high blood pressure, mood disorders (other than depression), stroke.

THIS FLU SEASON, PROTECT YOURSELF AND GET VACCINATED WITH FLUZONE® HIGH-DOSE!



Influenza season usually peaks in January or February, but can occur as early as October and as late as May. Early immunization is preferred, but it is not too late to get the vaccine in January or beyond.⁴

INFLUENZA IS RANKED:



among the most common infectious diseases in Canada^{4,10}



leading cause of mortality in Ontario between 2005-2007¹⁰

ACCORDING TO CANADA'S NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION (NACI):



There is evidence that a high dose vaccine (i.e., FLUZONE® High-Dose) provides superior protection over regular flu vaccine and it appears that high dose vaccine would provide the greatest benefit to people over age 65.¹¹

FLUZONE® HIGH-DOSE VACCINE:



Has been demonstrated to be significantly more effective than a standard dose vaccine in preventing confirmed influenza illness – **24.2% MORE EFFECTIVE.**¹²⁻¹³



Has **4 TIMES THE ANTIGEN** of a regular flu shot for a stronger protection against flu.⁴



Approximately **50 MILLION DOSES** distributed in the U.S. since 2009.¹⁴

ASK YOUR PHARMACIST FOR FLUZONE® HIGH-DOSE TODAY!

FLUZONE® High-Dose is a vaccine used to prevent influenza in adults 65 years of age and older. FLUZONE® High-Dose is not indicated for the prevention of complications, hospitalization or death after the onset of disease. As with all vaccines, FLUZONE® High-Dose does not protect 100% of people immunized. Side effects and allergic reactions can occur. For more information, visit www.fluzone.ca.

TALK TO YOUR HEALTHCARE PROVIDER ABOUT THE RISKS AND BENEFITS OF INFLUENZA VACCINATION.

REFERENCES: 1. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. *Immun Ageing*. 2007;4:9. 2. Monto AS, Ansaldo F, Aspinall R, et al. Influenza control in the 21st century: optimizing protection for older adults. *Vaccine*. 2009;27(37):5043-5053. 3. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. *JAMA*. 1994;272(21):1661-5. 4. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2015-2016. Public

Health Agency of Canada. July 2015. 5. CDC. Estimates of deaths associated with seasonal influenza—United States, 1976-2007. *MMWR*. 2010;59(33):1057-1062. 6. McElhaney J. Seasonal Influenza Vaccination: Public Health Benefits of Immunization in Non-Communicable Diseases – Implications for Policy White Paper. 7. Population by Sex and Age Group in Canada. Statistics Canada. 2015. 8. Public Health Agency of Canada (PHAC). FluWatch. May 3 to May 9, 2015. 9. CIHI: Seniors and the Health Care System: What Is the Impact of Multiple Chronic Conditions? 2011. Accessed at: https://secure.cihi.ca/free_products/air-chronic_disease_aib_en.pdf. 10. Kwong JC, Ratnasingham S, Campitelli MA, et al. The

Impact of Infection on Population Health: Results of the Ontario Burden of Infectious Diseases Study. *PLoS ONE*. 2012;7(9). 11. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI): Canadian Immunization Guide Chapter on Influenza and Interim Statement on Seasonal Influenza Vaccine for 2016-2017. Public Health Agency of Canada. 12. FLUZONE® High-Dose Product Monograph. Sanofi Pasteur Limited. May, 2016. 13. DiazGranados C., Dunning A., Kimmel M, et al. Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults. *N Engl J Med* 2014;371:635-45. 14. Sanofi Pasteur Inc. Data on file, FLUZONE® High-Dose Doses Distributed.